Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

  1. Gomez-Roca, C.
  2. Cassier, P.
  3. Zamarin, D.
  4. Machiels, J.-P.
  5. Luis Perez Gracia, J.
  6. Stephen Hodi, F.
  7. Taus, A.
  8. Martinez Garcia, M.
  9. Boni, V.
  10. Eder, J.P.
  11. Hafez, N.
  12. Sullivan, R.
  13. Mcdermott, D.
  14. Champiat, S.
  15. Aspeslagh, S.
  16. Terret, C.
  17. Jegg, A.-M.
  18. Jacob, W.
  19. Cannarile, M.A.
  20. Ries, C.
  21. Korski, K.
  22. Michielin, F.
  23. Christen, R.
  24. Babitzki, G.
  25. Watson, C.
  26. Meneses-Lorente, G.
  27. Weisser, M.
  28. Rüttinger, D.
  29. Delord, J.-P.
  30. Marabelle, A.
  31. Show all authors +
Journal:
Journal for immunotherapy of cancer

ISSN: 2051-1426

Year of publication: 2022

Volume: 10

Issue: 5

Type: Article

DOI: 10.1136/JITC-2021-004076 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus